In an in vivo mouse mammary tumour model, anti-MUC1 or anti-Her2 (C6MH3-B1) IgE therapy reduced mucin-1+ (MUC1+) or Her2+ tumour outgrowth, respectively, and improved the survival of tumour-bearing hFcεRI transgenic mice [45,47]. Here, ERBB2 is linked to neoplasm.